AI Article Synopsis
- CAM (Complementary and Alternative Medicine) is commonly used by cancer patients but can lead to significant interactions with both cancer therapies and medications for other health issues.
- A study focused on melanoma patients found that 37.2% were at risk for harmful interactions between CAM and their conventional drugs, especially among those using Chinese herbs (88.6%).
- The findings highlight the need for healthcare providers to routinely assess CAM usage alongside traditional medications to ensure patient safety in cancer care.
Article Abstract
Complementary and alternative medicine (CAM) is used widely among cancer patients. Beside the risk of interaction with cancer therapies, interactions with treatment for comorbidities are an underestimated problem. The aim of this study was to assess prevalence of interactions between CAM and drugs for comorbidities from a large CAM usage survey on melanoma patients and to classify herb-drug interactions with regard to their potential to harm. Consecutive melanoma outpatients of seven skin cancer centers were asked to complete a standardized CAM questionnaire including questions to their CAM use and their taken medication for comorbidities and cancer. Each combination of conventional drugs and complementary substances was evaluated for their potential of interaction. 1089 questionnaires were eligible for evaluation. From these, 61.6% of patients reported taking drugs regularly from which 34.4% used biological-based CAM methods. Risk evaluation for interaction was possible for 180 CAM users who listed the names or substances they took for comorbidities. From those patients, we found 37.2% at risk of interaction of their co-consumption of conventional and complementary drugs. Almost all patients using Chinese herbs were at risk (88.6%). With a high rate of CAM usage at risk of interactions between CAM drugs and drugs taken for comorbidities, implementation of a regular assessment of CAM usage and drugs for comorbidities is mandatory in cancer care.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1007/s12032-016-0764-6 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Prevalence and factors associated with potential clinically significant drug-drug interactions in patients with cardiovascular diseases at hospital admission.
Acta Pharm
December 2024
Department of Clinical Pharmacy, University Hospital Dubrava, 10000 Zagreb Croatia.
Cardiovascular diseases (CVDs) are the leading cause of mortality and morbidity globally. It is estimated that 17.9 million people died from CVDs in 2019, which represents 32 % of all deaths worldwide.
View Article and Find Full Text PDFTrends in prescribing montelukast in patients with asthma in real-life: Results from the Turkish adult asthma registry.
Allergol Immunopathol (Madr)
January 2025
Department of Chest Disease, Division of Immunology and Allergy, Ankara University School of Medicine, Ankara, Turkey.
Montelukast, a leukotriene receptor antagonist (LTRA) approved for the treatment of asthma and allergic rhinitis, is widely used, though real-world data on its application in asthma management remain limited. This registry-based study evaluated the use of montelukast in adult asthma patients, examining demographic and disease characteristics, asthma control status, asthma phenotypes, presence of atopy, and treatment regimens. Among 2053 patients analyzed, 61.
View Article and Find Full Text PDFBackground: Over half of ambulatory older adults are prescribed at least one anticholinergic medication to address a myriad of conditions, including incontinence, allergies, anxiety and insomnia. Longitudinal studies suggest an association between anticholinergic exposure and risk of dementia. Prior studies often rely on crude exposure measures (use vs.
View Article and Find Full Text PDFBackground: Evidence for abnormal amyloid-β (Aβ) plaque accumulation is necessary prior to initiating anti-amyloid therapy in early symptomatic Alzheimer's disease (AD). While the clinical trials for lecanemab and related drugs utilized positron emission tomography (PET) to demonstrate brain amyloidosis, current appropriate use recommendations for clinical practice consider PET or cerebrospinal fluid (CSF) biomarkers as satisfactory for this purpose. Here, we present four clinical cases where CSF biomarker results were discordant from amyloid PET, with the potential to result in erroneous treatment targeting.
View Article and Find Full Text PDFBackground: Lecanemab has been approved by the FDA for patients with early Alzheimer's disease (AD). NA-831 is an experimental drug that has showed a proof of safety and efficacy in Phase 2 clinical trial for patients with early Alzheimer's disease. AD patients are treated with a number of comedications not only to address cognitive impairment (standard-of-care) but also other comorbidities.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!